Changes for page Jubilant Pharmova Limited
Last modified by Asif Farooqui on 2021/06/16 06:17
Change comment:
There is no comment for this version
Summary
-
Page properties (1 modified, 0 added, 0 removed)
-
Attachments (0 modified, 4 added, 0 removed)
Details
- Page properties
-
- Content
-
... ... @@ -2,13 +2,11 @@ 2 2 {{toc/}} 3 3 {{/box}} 4 4 5 -Company Overview 5 += Company Overview = 6 6 7 -Pharmova is born out of a combination of ‘Pharma’ and ‘Nova’ (New) and Jubilant Pharmova Limited will continue to focus on offering products and services with, excellence in research and manufacturing, catering to the unmet health needs at an affordable price. 7 +Pharmova is born out of a combination of ‘Pharma’ and ‘Nova’ (New) and Jubilant Pharmova Limited will continue to focus on offering products and services with, excellence in research and manufacturing, catering to the unmet health needs at an affordable price. {{footnote}}https://www.jubilantpharmova.com{{/footnote}} 8 8 9 -[[https:~~/~~/www.jubilantpharmova.com>>url:https://www.jubilantpharmova.com]] 10 10 11 - 12 12 It is an integrated global pharmaceuticals company having three business segments Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs. 13 13 14 14 ... ... @@ -24,97 +24,79 @@ 24 24 Jubilant Pharmova Limited has a team of around 7,700 multicultural people across the globe and is committed to delivering value to its customers in over 100 countries. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies worldwide. 25 25 26 26 27 - Business Segments25 +[[image:JUBLPHARMA1.png]] 28 28 29 -Pharmaceuticals 30 30 31 - JubilantPharma Limited is a global integrated pharmaceutical company offering a wide range of productsand services to its customers across geographies. The company organizeitspharma businessinto three segments. Firstly, ‘Specialty Pharmaceuticals’ comprisingRadiopharmaceuticals (including Radiopharmacies) and Allergy Therapy Products.its ‘CDMO’ segment, comprising Contract Manufacturing for Non-Oral Formulation and Active Pharmaceutical Ingredients.28 += Business Segments = 32 32 33 - [[https:~~/~~/www.jubilantpharma.com/about-us/about-jubilant-pharma>>url:https://www.jubilantpharma.com/about-us/about-jubilant-pharma]]30 +== Pharmaceuticals == 34 34 32 +Jubilant Pharma Limited is a global integrated pharmaceutical company offering a wide range of products and services to its customers across geographies. The company organize its pharma business into three segments. Firstly, ‘Specialty Pharmaceuticals’ comprising Radiopharmaceuticals (including Radiopharmacies) and Allergy Therapy Products. its ‘CDMO’ segment, comprising Contract Manufacturing for Non-Oral Formulation and Active Pharmaceutical Ingredients. {{footnote}}https://www.jubilantpharma.com/about-us/about-jubilant-pharma{{/footnote}} 35 35 36 36 The company supply its products and services to customers in over 85 countries. Jubilant Pharmova has four manufacturing facilities in North America and two in India, coupled with Research and Development centres in North America and India. Additionally, Jubilant Pharmova has a distribution network of more than 45 radiopharmacies in the United States. 37 37 38 38 39 -Radiopharmaceuticals 37 +**Radiopharmaceuticals** 40 40 41 - 42 42 Third largest radiopharmaceutical manufacturer in the nuclear medicine industry in the United States based on revenue 43 43 44 44 Second largest centralized commercial radiopharmacy network in the United States with a national footprint of more than 45 radiopharmacies across 22 states 45 45 46 46 47 -Allergy Therapy Products 44 +**Allergy Therapy Products** 48 48 49 49 One of the top three players with a market share of 25% in the allergenic extract market in the United States and are currently the sole producer and supplier of venom products for the treatment of allergies in the United States 50 50 51 51 52 -APIs 49 +**APIs** 53 53 54 54 Among the leading global suppliers for several Key APIs. 55 55 56 56 57 -Solid Dosage Formulations 54 +**Solid Dosage Formulations** 58 58 59 59 One of the market leaders in the United States, based on market share of several key products 60 60 61 61 62 -Contract Research and Development Services 59 +== Contract Research and Development Services == 63 63 64 -Jubilant Biosys Ltd is a part of the Jubilant Pharmova family of companies with R&D centers in India and business offices in Asia and North America. With its global reach, Jubilant Biosys provides comprehensive drug discovery services and contract research services–from target discovery to candidate selection and with flexible business models (FFS, FTE and risk shared)–in partnership with leading worldwide healthcare companies. 61 +Jubilant Biosys Ltd is a part of the Jubilant Pharmova family of companies with R&D centers in India and business offices in Asia and North America. With its global reach, Jubilant Biosys provides comprehensive drug discovery services and contract research services–from target discovery to candidate selection and with flexible business models (FFS, FTE and risk shared)–in partnership with leading worldwide healthcare companies. {{footnote}}https://www.jubilantbiosys.com/about-us/company-overview/{{/footnote}} 65 65 66 -[[https:~~/~~/www.jubilantbiosys.com/about-us/company-overview/>>url:https://www.jubilantbiosys.com/about-us/company-overview/]] 67 67 68 - 69 69 With a clear scientific focus in oncology, metabolic disorders, central nervous system (CNS) diseases, pain and inflammation, Jubilant Biosys has rapidly emerged as a leading collaborator for pharmaceutical and biotechnology companies worldwide. In each of these therapeutic areas, Jubilant Biosys has developed a deep level of expertise in discovery informatics, computational chemistry, medicinal chemistry, structural biology, biology, in-vivo, in-vitro models and translational sciences. Combined with strong clinical development and manufacturing capabilities from other Jubilant subsidiaries, Jubilant Biosys has risen as a fully integrated contract research organization in India and headquartered at Bengaluru with end-to-end solutions. 70 70 71 71 72 72 The company's ability to be the preferred collaborator in the drug discovery domain is sustained by its commitment to comply with and continually improve its quality systems and to provide the following services: 73 73 69 +* Contract Research 70 +* Preclinical CRO 71 +* Drug Discovery 72 +* Virtual Screening 73 +* Protein Crystallization 74 +* Toxicology & In-vitro ADME 75 +* Medicinal Chemistry 76 +* Synthetic & Developmental Chemistry 77 +* Pharmacology 74 74 75 -. 76 - 77 -Contract Research 78 - 79 -Preclinical CRO 80 - 81 -Drug Discovery 82 - 83 -Virtual Screening 84 - 85 -Protein Crystallization 86 - 87 -Toxicology & In-vitro ADME 88 - 89 -Medicinal Chemistry 90 - 91 -Synthetic & Developmental Chemistry 92 - 93 -Pharmacology 94 - 95 - 96 96 Jubilant Biosys collaborates with the world’s leading pharmaceutical, biotech companies, academic institutions and research foundations. 97 97 98 98 82 +== Proprietary Novel Drugs == 99 99 100 -Proprietary Novel Drugs 101 - 102 102 Jubilant Therapeutics is a patient-centric biopharmaceutical company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases. 103 103 104 104 105 -<img pipline> 106 106 88 +[[image:JUBLPHARMApipe.jpg]] 107 107 108 108 109 109 110 -Industry Overview 92 += Industry Overview = 111 111 112 112 113 -As per IMF’s June 2020 World Economic Outlook update, in 2020 the global economy is expected to witness the worst recession since the Great Depression with economic output likely to contract by 4.9%. This is attributed to the damage caused by the lockdowns implemented by several large economies that resulted in disruption in supply chains, demand destruction and rapid increase in unemployment levels across several large economies. In 2020, the IMF expects the Advanced Economies to contract by 8% with the US economy likely to shrink by 8% and the Euro region by 10.2%. The Emerging markets also are expected to be severely impacted and are expected to contract by 3% in 2020 with China’s growth rate expected to decline to 1% and the Indian economy expected to contract by 4.5% in FY 2021. 95 +As per IMF’s June 2020 World Economic Outlook update, in 2020 the global economy is expected to witness the worst recession since the Great Depression with economic output likely to contract by 4.9%. This is attributed to the damage caused by the lockdowns implemented by several large economies that resulted in disruption in supply chains, demand destruction and rapid increase in unemployment levels across several large economies. In 2020, the IMF expects the Advanced Economies to contract by 8% with the US economy likely to shrink by 8% and the Euro region by 10.2%. The Emerging markets also are expected to be severely impacted and are expected to contract by 3% in 2020 with China’s growth rate expected to decline to 1% and the Indian economy expected to contract by 4.5% in FY 2021. {{footnote}}https://www.jubilantpharmova.com/uploads/downloads/JubilantLifeSciencesAnnualReport2019-20.pdf{{/footnote}} 114 114 115 -[[https:~~/~~/www.jubilantpharmova.com/uploads/downloads/JubilantLifeSciencesAnnualReport2019-20.pdf>>url:https://www.jubilantpharmova.com/uploads/downloads/JubilantLifeSciencesAnnualReport2019-20.pdf]] 116 116 117 - 118 118 Government and central banks across the world have resorted to unprecedented fiscal and monetary stimulus to mitigate the impact of COVID-19 and support economic activity, which is expected to lead to recovery in 2021. In 2021, IMF expects the global economy to grow by 5.4% with US and Euro region growing by 4.5% and 6% and Chinese and Indian economies growing by 8.2% and 6%, respectively. However, given the evolving pandemic situation, there is considerable uncertainty about the strength of the recovery and if the world witnesses a prolonged impact of COVID-19, then economic output and short-term outlook may further get impacted. 119 119 120 120 As per Evaluate Pharma’s annual ‘World Preview’, the global Prescription drug sales is expected to grow at 6.9% Compound Annual Growth Rate (CAGR) between 2019- 2024 to reach US$ 1.2 trillion. This growth is expected to be driven by immuno-oncology line extensions and emergence of novel technologies such as cell and gene therapy. ... ... @@ -128,10 +128,12 @@ 128 128 The global crop protection chemicals market size was US$ 58.4 billion in 2019 and is anticipated to expand at a CAGR of 3.3% from 2020 to 2027. Greater emphasis on high crop output to counter food security is the key growth driver. 129 129 130 130 131 - Financial Overview111 +[[image:JUBLPHARMA2.png]] 132 132 133 133 114 += Financial Overview = 134 134 116 + 135 135 Total Revenue from Operations during the year ended March 31, 2020 stood at Rs 91,544 million as compared to Rs 91,108 million in FY 2019. Revenue from Pharmaceuticals segment grew 7% YoY at Rs 57,143 million contributing 62% to overall revenue. Revenue from Life Science Ingredients segment was at Rs 31,786 million in the year as compared to Rs 35,452 million in previous year. Revenue from Drug Discovery & Development Solutions segment stood at Rs 2,615 million in the year contributing 3% to the total revenue. 136 136 137 137 ... ... @@ -142,47 +142,43 @@ 142 142 The Profit After Tax was at Rs 8,982 million in FY 2020 up from Rs 5,745 million in FY 2019. Earnings per Share (EPS) during the year was at Rs 56.39 per equity share of Rs 1 each vs. Rs 36.86 in FY 2019. 143 143 144 144 145 -Pharmaceuticals segment 127 +**Pharmaceuticals segment** 146 146 147 147 The Pharmaceuticals segment is engaged in the manufacture, supply and distribution of Radiopharmaceuticals, Allergy Therapy Products, Contract Manufacturing (CMO) of Sterile injectables and Non-sterile products, Active Pharmaceutical Ingredients (APIs), Solid Dosage Formulations and India Branded Pharmaceuticals through six US FDA approved facilities in the US, Canada and India and contributes 62% to its Total Revenue from Operations. Revenue from this segment has improved 7% YoY to Rs 57,143 million from Rs 53,488 million last year. 148 148 149 149 150 -Life Science Ingredients segment 132 +**Life Science Ingredients segment** 151 151 152 152 Revenue contribution from the Life Science Ingredients segment to Total revenue from operations stood at 35%. During the year segment revenue was at Rs 31,786 million as against Rs 35,452 million in FY 2019. 153 153 154 154 155 -Drug Discovery & Development Solutions (DDDS) 137 +**Drug Discovery & Development Solutions (DDDS)** 156 156 157 157 The Drug Discovery & Development Solutions (DDDS) segment includes its Drug Discovery Services (Jubilant Biosys Limited and Jubilant Chemsys Limited) & Proprietary Drug Discovery (Jubilant Therapeutics Inc.) businesses. Revenues in FY 2020 were at Rs 2,615 million as compared to Rs 2,168 million in the previous year, up 21% YoY. 158 158 159 159 160 - FY21 results142 +[[image:JUBLPHARMA3.png]] 161 161 162 162 163 - JubilantPharmova reports net profit of Rs 214 crore in Q4;FY21profitat Rs836 crore145 +== FY21 results == 164 164 165 -[[https:~~/~~/www.moneycontrol.com/news/business/earnings/jubilant-pharmova-reports-net-profit-of-rs-214-crore-in-q4-fy21-profit-at-rs-836-crore-6992441.html>>url:https://www.moneycontrol.com/news/business/earnings/jubilant-pharmova-reports-net-profit-of-rs-214-crore-in-q4-fy21-profit-at-rs-836-crore-6992441.html]] 166 166 148 +**Jubilant Pharmova reports net profit of Rs 214 crore in Q4; FY21 profit at Rs 836 crore. **{{footnote}}https://www.moneycontrol.com/news/business/earnings/jubilant-pharmova-reports-net-profit-of-rs-214-crore-in-q4-fy21-profit-at-rs-836-crore-6992441.html{{/footnote}} 167 167 150 + 168 168 Drug firm Jubilant Pharmova on Friday reported a consolidated net profit of Rs 214 crore for the fourth quarter ended March 31, 2021. The company had posted a net profit of Rs 260 crore in the January-March quarter of 2019-20. 169 169 170 - 171 171 Sales stood at Rs 1,552 crore for the fourth quarter while the same was at Rs 1,497 crore in the same period of FY20. 172 172 173 - 174 174 For the entire 2020-21 fiscal, the company reported a consolidated net profit of Rs 836 crore. It was Rs 898 crore in FY20. 175 175 176 - 177 177 Sales of the company last fiscal stood at Rs 5,964 crore, while the same was Rs 5,843 crore in FY20. 178 178 179 - 180 180 The drug firm noted that the figures for the current quarter and year were not comparable with previous periods since the Life Science Ingredients (LSI) business demerged from it with effect from February 1, 2021. 181 181 182 182 183 183 "…despite COVID-19 challenges, revenues were stable due to a diverse range of businesses. CDMO and Generics grew though the company saw impact on radiopharma and had production impact at the Nanjangud API plant," Jubilant Pharmova Chairman Shyam S Bhartia said in a regulatory filing. 184 184 185 - 186 186 Despite the pandemic-related lockdowns, the company has been able to ensure continuity in most of its manufacturing operations across all business segments while at the same time ensuring safety of employees, he added. 187 187 188 188 ... ... @@ -191,20 +191,17 @@ 191 191 192 192 On generics business, the company noted it plans to launch new products in the US via in-licensing and contract manufacturing. 193 193 194 - 195 195 "The company expect to launch new products from the Roorkee site once the warning letter is lifted. The company plan to enhance geographical reach in the rest of the world (RoW) markets," it added. 196 196 197 - 198 198 The company's board has recommended a dividend of Rs 5 per share of Re 1 each, aggregating to around Rs 80 crore, for the financial year ended March 31, 2021. 199 199 200 200 201 -Business Outlook 177 +== Business Outlook == 202 202 203 203 . 204 204 205 -Radiopharma: The company continue to build a long term pipeline of radiopharmaceuticals including Generics as well as Proprietary products being used as Diagnostic, Therapeutic, Theranostic and Devices, via in-house R&D as well as strategic partnerships with key nuclear medicine companies 181 +Radiopharma: The company continue to build a long term pipeline of radiopharmaceuticals including Generics as well as Proprietary products being used as Diagnostic, Therapeutic, Theranostic and Devices, via in-house R&D as well as strategic partnerships with key nuclear medicine companies {{footnote}}https://www.jubilantpharmova.com/Uploads/files/80q1consfileQ4-FY21PressRelease.pdf{{/footnote}} 206 206 207 -[[https:~~/~~/www.jubilantpharmova.com/Uploads/files/80q1consfileQ4-FY21PressRelease.pdf>>url:https://www.jubilantpharmova.com/Uploads/files/80q1consfileQ4-FY21PressRelease.pdf]] 208 208 209 209 The company expect one product launch in radiopharma in FY22. Jubilant Pharmova is further enhancing marketing and business development efforts for Ruby-Fill 210 210 ... ... @@ -231,4 +231,6 @@ 231 231 Consolidated effective tax rate: ETR of Jubilant Pharmova Limited (Continuing Operations) for FY21 is 34.1%. The company’s cash tax outflow is estimated to be at approximately 24% for the next three years. After exhaustion of the MAT credit, the Company’s effective tax rate is expected to come down to around 25% in three years’ timeframe 232 232 233 233 234 -References 209 += References = 210 + 211 +{{putFootnotes/}}
- JUBLPHARMA1.png
-
- Author
-
... ... @@ -1,0 +1,1 @@ 1 +XWiki.AsifF - Size
-
... ... @@ -1,0 +1,1 @@ 1 +181.7 KB - Content
- JUBLPHARMA2.png
-
- Author
-
... ... @@ -1,0 +1,1 @@ 1 +XWiki.AsifF - Size
-
... ... @@ -1,0 +1,1 @@ 1 +194.2 KB - Content
- JUBLPHARMA3.png
-
- Author
-
... ... @@ -1,0 +1,1 @@ 1 +XWiki.AsifF - Size
-
... ... @@ -1,0 +1,1 @@ 1 +47.8 KB - Content
- JUBLPHARMApipe.jpg
-
- Author
-
... ... @@ -1,0 +1,1 @@ 1 +XWiki.AsifF - Size
-
... ... @@ -1,0 +1,1 @@ 1 +107.6 KB - Content